核酸增幅檢查市場分析及預測（至2035年）：依類型、產品類型、技術、應用、最終用戶、組件、製程、設備及模式分類

核酸增幅檢查市場預計將從2024年的106億美元成長到2034年的366億美元，複合年成長率約為14.5%。核酸增幅檢查市場涵蓋了擴增核酸以檢測病原體、基因突變或生物標記的診斷技術。這些方法，包括PCR和等溫擴增，在感染疾病診斷、腫瘤學和個人化醫療中至關重要。對快速準確診斷日益成長的需求，以及技術的進步，正在推動市場成長，其中自動化、高靈敏度和照護現場解決方案尤其重要。

核酸增幅檢查(NAAT) 市場正經歷強勁成長，這主要得益於分子診斷技術的進步以及對精準病原體檢測需求的不斷成長。聚合酵素鏈鎖反應(PCR) 是成長最快的細分市場，因其準確性和在臨床診斷中的廣泛應用而備受認可。即時PCR作為 PCR 的一個子集，因其快速通量和定量分析能力而特別突出。轉錄媒介增幅(TMA) 是第二大成長最快的細分市場，這主要歸功於其在感染疾病檢測方面卓越的靈敏度和速度。在終端用戶領域，醫院和診斷檢查室主導NAAT 的發展，這主要得益於 NAAT 在疾病早期檢測和管理方面的應用日益廣泛。研究機構和學術中心是第二大盈利最快的細分市場，它們利用這些技術進行創新研發。對個人化醫療的日益重視以及對快速可靠診斷解決方案的需求正在推動 NAAT 市場的發展，並為相關人員提供了盈利的機會。

核酸增幅檢查(NAAT) 市場的特點是市場佔有率分佈動態變化、定價策略複雜以及創新產品層出不窮。 NAAT 以其準確性和快速檢測結果而聞名，在各個細分市場中展現出強勁的需求。各公司正透過具競爭力的價格和尖端產品的推出，進行策略性佈局以搶佔市場佔有率。持續的技術進步進一步加劇了這種競爭環境，提升了產品的差異化和市場吸引力。 NAAT 市場由少數主要企業主導，這些企業利用技術創新來保持其競爭優勢。基準研究表明，這些公司正致力於拓展產品系列併提高營運效率。監管因素，特別是北美和歐洲的嚴格指導方針，透過設定高標準的產品品質和安全要求，正在塑造市場動態。這些法規在帶來挑戰的同時，也為企業提供了創新和產品差異化的機遇，進而影響市場成長和普及。

主要趨勢和促進因素：

核酸增幅檢查(NAAT) 市場正經歷強勁成長，這主要得益於分子診斷技術的進步以及對快速、準確檢測解決方案日益成長的需求。一個關鍵趨勢是將 NAAT 與就地檢驗設備結合，從而實現疾病的快速診斷和管理。這一趨勢在感染疾病防治領域尤其明顯，因為及時干預至關重要。此外，個人化醫療的興起也推動了市場發展。 NAAT 擴大應用於基因檢測，有助於制定個人化治療方案，從而改善患者預後。市場也受惠於技術創新，例如等溫擴增技術的開發，該技術能夠提供更快、更經濟高效的檢測結果。此外，COVID-19 疫情凸顯了完善的偵測基礎設施的重要性，加速了 NAAT 在全球醫療系統中的應用。新興市場蘊藏著許多機遇，這些市場的醫療基礎設施正在不斷完善，人們對疾病的早期檢測和預防也越來越感興趣。能夠提供擴充性、高效且經濟實惠的檢測解決方案的公司有望佔據顯著的市場佔有率。對改善醫療服務和治療效果的關注將繼續推動對 NAAT 技術的需求。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機遇
• 市場限制
• 複合年均成長率：成長分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 聚合酵素鏈鎖反應（PCR）
  • 等溫擴增
  • 連接酶鍊式反應（LCR）
  • 轉錄媒介增幅（TMA）
  • 鏈置換擴增（SDA）
  • 解旋酶依賴性擴增（HDA）
  • 恒溫環型核酸擴增（LAMP）
• 市場規模及預測：依產品分類
  • 裝置
  • 試劑和耗材
  • 軟體和服務
• 市場規模及預測：依技術分類
  • 即時PCR
  • 數位PCR
  • 多重PCR
• 市場規模及預測：依應用領域分類
  • 感染疾病
  • 癌症
  • 基因檢測
  • 法醫檢驗
  • 血液篩檢
• 市場規模及預測：依最終用戶分類
  • 醫院和診斷檢查室
  • 研究所
  • 生物技術和製藥公司
  • 合約研究機構
• 市場規模及預測：依組件分類
  • 試劑盒和檢測
  • 分析器
• 市場規模及預測：依製程分類
  • 樣品製備
  • 放大
  • 偵測
• 市場規模及預測：依設備分類
  • 聚合酵素連鎖反應熱迴圈儀
  • 自動核酸萃取裝置
• 市場規模及預測：依方法
  • 實驗室測試
  • 研究與測試

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地區
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 亞太其他地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲地區

第6章 市場策略

• 需求與供給差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 法規概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要企業的策略

第8章 公司簡介

• Bio-Rad Laboratories
• Luminex Corporation
• Cepheid
• Dia Sorin
• QIAGEN
• Hologic
• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• bio Merieux
• Agilent Technologies
• Illumina
• Perkin Elmer
• Tecan Group
• Promega Corporation
• Gen Mark Diagnostics
• Quidel Corporation
• Meridian Bioscience
• Fluidigm Corporation
• Bio Fire Diagnostics

第9章：關於我們

Nucleic Acid Amplification Testing Market is anticipated to expand from $10.6 billion in 2024 to $36.6 billion by 2034, growing at a CAGR of approximately 14.5%. The Nucleic Acid Amplification Testing Market encompasses diagnostic techniques that amplify nucleic acids to detect pathogens, genetic mutations, or biomarkers. These methods, including PCR and isothermal amplification, are pivotal in infectious disease diagnosis, oncology, and personalized medicine. Rising demand for rapid and accurate diagnostics, coupled with technological advancements, propels market growth, emphasizing automation, sensitivity, and point-of-care solutions.

The Nucleic Acid Amplification Testing (NAAT) Market is experiencing robust growth, fueled by advancements in molecular diagnostics and heightened demand for precise pathogen detection. The polymerase chain reaction (PCR) segment is the top-performing sub-segment, revered for its accuracy and widespread application in clinical diagnostics. Real-time PCR, a subset, is particularly prominent due to its rapid processing capabilities and quantitative analysis. The transcription-mediated amplification (TMA) segment follows as the second highest-performing, offering advantages in sensitivity and speed for detecting infectious diseases. In the end-user landscape, the hospital and diagnostic laboratories segment leads, driven by the increasing adoption of NAAT for early disease detection and management. Research institutes and academic centers are the second most lucrative, as they leverage these technologies for innovative research and development. The growing emphasis on personalized medicine and the need for rapid, reliable diagnostic solutions propel the NAAT market forward, offering lucrative opportunities for stakeholders.

The Nucleic Acid Amplification Testing (NAAT) market is characterized by a dynamic landscape of market share distribution, pricing strategies, and innovative product launches. Renowned for its precision and rapid results, the NAAT market is witnessing robust demand across various sectors. Companies are strategically positioning themselves through competitive pricing and the introduction of cutting-edge products to capture market share. This competitive environment is further intensified by the continuous advancement in technology, which drives product differentiation and enhances market appeal. In terms of competition, the NAAT market is dominated by a few key players who are leveraging technological advancements to maintain their competitive edge. Benchmarking reveals that these players are focusing on expanding their product portfolios and enhancing operational efficiency. Regulatory influences, particularly stringent guidelines in North America and Europe, are shaping market dynamics by setting high standards for product quality and safety. These regulations, while challenging, also present opportunities for companies to innovate and differentiate their offerings, thereby influencing market growth and adoption.

Geographical Overview:

The Nucleic Acid Amplification Testing (NAAT) market is witnessing notable growth across various regions, each presenting unique opportunities. North America remains a dominant player, driven by advanced healthcare infrastructure and increasing demand for accurate diagnostic tools. The region's focus on precision medicine further propels market expansion. Europe follows closely, with strong investments in biotechnology and a robust regulatory framework supporting NAAT adoption. Asia Pacific is emerging as a significant growth pocket, fueled by rising healthcare expenditures and technological advancements. Countries like China and India are at the forefront, investing heavily in diagnostic technologies to enhance healthcare outcomes. Latin America and the Middle East & Africa are also gaining traction, with increasing awareness and adoption of NAAT for infectious disease management. Brazil and South Africa are notable emerging markets, recognizing the importance of advanced diagnostic solutions in improving public health and driving economic growth.

The global tariff landscape and geopolitical tensions are significantly influencing the Nucleic Acid Amplification Testing Market. Japan and South Korea are navigating US-China trade tensions by bolstering domestic production capabilities and investing in biotechnological innovation. China's strategy focuses on reducing dependency on foreign technologies, fostering home-grown advancements in nucleic acid testing technologies. Taiwan, a pivotal player in semiconductor supply chains, faces geopolitical risks but remains integral to the market's growth. The parent market is experiencing robust global demand driven by increased healthcare awareness and infectious disease control. By 2035, market evolution will hinge on supply chain resilience and technological self-reliance. Middle East conflicts could exacerbate global supply chain disruptions and elevate energy prices, indirectly affecting production costs and market dynamics.

Key Trends and Drivers:

The Nucleic Acid Amplification Testing (NAAT) market is experiencing robust growth driven by advancements in molecular diagnostics and increased demand for rapid and accurate testing solutions. A key trend is the integration of NAAT with point-of-care testing devices, allowing for swift disease diagnosis and management. This trend is particularly pronounced in infectious disease control, where timely intervention is critical. Moreover, the rise of personalized medicine is propelling the market forward. NAAT is increasingly utilized in genetic testing, enabling tailored treatment plans that improve patient outcomes. The market is also benefiting from technological innovations, such as the development of isothermal amplification techniques that offer faster results and are more cost-effective. Additionally, the COVID-19 pandemic has underscored the importance of robust testing infrastructure, accelerating the adoption of NAAT across healthcare systems globally. Opportunities abound in emerging markets where healthcare infrastructure is expanding, and there is a growing emphasis on early disease detection and prevention. Companies that can offer scalable, efficient, and affordable testing solutions are poised to capture significant market share. The focus on improving healthcare access and outcomes will continue to drive demand for NAAT technologies.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Component
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Equipment
• 2.9 Key Market Highlights by Mode

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Polymerase Chain Reaction (PCR)
  • 4.1.2 Isothermal Amplification
  • 4.1.3 Ligase Chain Reaction (LCR)
  • 4.1.4 Transcription Mediated Amplification (TMA)
  • 4.1.5 Strand Displacement Amplification (SDA)
  • 4.1.6 Helicase-Dependent Amplification (HDA)
  • 4.1.7 Loop-Mediated Isothermal Amplification (LAMP)
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Instruments
  • 4.2.2 Reagents and Consumables
  • 4.2.3 Software and Services
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Real-Time PCR
  • 4.3.2 Digital PCR
  • 4.3.3 Multiplex PCR
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Infectious Diseases
  • 4.4.2 Cancer
  • 4.4.3 Genetic Testing
  • 4.4.4 Forensic Testing
  • 4.4.5 Blood Screening
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals and Diagnostic Laboratories
  • 4.5.2 Research Institutes
  • 4.5.3 Biotechnology and Pharmaceutical Companies
  • 4.5.4 Contract Research Organizations
• 4.6 Market Size & Forecast by Component (2020-2035)
  • 4.6.1 Kits and Assays
  • 4.6.2 Analyzers
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Sample Preparation
  • 4.7.2 Amplification
  • 4.7.3 Detection
• 4.8 Market Size & Forecast by Equipment (2020-2035)
  • 4.8.1 Thermal Cyclers
  • 4.8.2 Automated Nucleic Acid Extractors
• 4.9 Market Size & Forecast by Mode (2020-2035)
  • 4.9.1 Clinical Testing
  • 4.9.2 Research Testing

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Component
    • 5.2.1.7 Process
    • 5.2.1.8 Equipment
    • 5.2.1.9 Mode
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Component
    • 5.2.2.7 Process
    • 5.2.2.8 Equipment
    • 5.2.2.9 Mode
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Component
    • 5.2.3.7 Process
    • 5.2.3.8 Equipment
    • 5.2.3.9 Mode
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Component
    • 5.3.1.7 Process
    • 5.3.1.8 Equipment
    • 5.3.1.9 Mode
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Component
    • 5.3.2.7 Process
    • 5.3.2.8 Equipment
    • 5.3.2.9 Mode
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Component
    • 5.3.3.7 Process
    • 5.3.3.8 Equipment
    • 5.3.3.9 Mode
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Component
    • 5.4.1.7 Process
    • 5.4.1.8 Equipment
    • 5.4.1.9 Mode
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Component
    • 5.4.2.7 Process
    • 5.4.2.8 Equipment
    • 5.4.2.9 Mode
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Component
    • 5.4.3.7 Process
    • 5.4.3.8 Equipment
    • 5.4.3.9 Mode
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Component
    • 5.4.4.7 Process
    • 5.4.4.8 Equipment
    • 5.4.4.9 Mode
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Component
    • 5.4.5.7 Process
    • 5.4.5.8 Equipment
    • 5.4.5.9 Mode
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Component
    • 5.4.6.7 Process
    • 5.4.6.8 Equipment
    • 5.4.6.9 Mode
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Component
    • 5.4.7.7 Process
    • 5.4.7.8 Equipment
    • 5.4.7.9 Mode
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Component
    • 5.5.1.7 Process
    • 5.5.1.8 Equipment
    • 5.5.1.9 Mode
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Component
    • 5.5.2.7 Process
    • 5.5.2.8 Equipment
    • 5.5.2.9 Mode
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Component
    • 5.5.3.7 Process
    • 5.5.3.8 Equipment
    • 5.5.3.9 Mode
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Component
    • 5.5.4.7 Process
    • 5.5.4.8 Equipment
    • 5.5.4.9 Mode
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Component
    • 5.5.5.7 Process
    • 5.5.5.8 Equipment
    • 5.5.5.9 Mode
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Component
    • 5.5.6.7 Process
    • 5.5.6.8 Equipment
    • 5.5.6.9 Mode
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Component
    • 5.6.1.7 Process
    • 5.6.1.8 Equipment
    • 5.6.1.9 Mode
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Component
    • 5.6.2.7 Process
    • 5.6.2.8 Equipment
    • 5.6.2.9 Mode
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Component
    • 5.6.3.7 Process
    • 5.6.3.8 Equipment
    • 5.6.3.9 Mode
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Component
    • 5.6.4.7 Process
    • 5.6.4.8 Equipment
    • 5.6.4.9 Mode
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Component
    • 5.6.5.7 Process
    • 5.6.5.8 Equipment
    • 5.6.5.9 Mode

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Bio- Rad Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Luminex Corporation
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Cepheid
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Dia Sorin
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 QIAGEN
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Hologic
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Thermo Fisher Scientific
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Roche Diagnostics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Abbott Laboratories
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 bio Merieux
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Agilent Technologies
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Illumina
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Perkin Elmer
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Tecan Group
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Promega Corporation
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Gen Mark Diagnostics
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Quidel Corporation
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Meridian Bioscience
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Fluidigm Corporation
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Bio Fire Diagnostics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us